[Federal Register Volume 79, Number 49 (Thursday, March 13, 2014)]
[Notices]
[Pages 14298-14299]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-05489]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration; 
Nektar Therapeutics

    By Notice dated September 27, 2013, and published in the Federal 
Register on October 25, 2013, 78 FR 64018, Nektar Therapeutics, 1112 
Church Street, Huntsville, Alabama 35801, made application by renewal 
to the Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of Fentanyl (9801), a basic

[[Page 14299]]

class of controlled substance listed in schedule II.
    The company plans to manufacture the listed controlled substance in 
support of product development.
    No comments or objections have been received. The DEA has 
considered the factors in 21 U.S.C. 823(a) and determined that the 
registration of Nektar Therapeutics to manufacture the listed basic 
class of controlled substance is consistent with the public interest at 
this time. The DEA has investigated Nektar Therapeutics to ensure that 
the company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history.
    Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 
1301.33, the above named company is granted registration as a bulk 
manufacturer of the basic class of controlled substance listed.

    Dated: Signed February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2014-05489 Filed 3-12-14; 8:45 am]
BILLING CODE 4410-09-P